Chia‐Chi Lin

1.1k total citations
44 papers, 835 citations indexed

About

Chia‐Chi Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chia‐Chi Lin has authored 44 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Chia‐Chi Lin's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Chia‐Chi Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Chia‐Chi Lin collaborates with scholars based in Taiwan, United States and South Korea. Chia‐Chi Lin's co-authors include James Chih‐Hsin Yang, Bin-Chi Liao, Pei‐Jie Meng, Te-Hao Chen, Andrea Harzstark, Eric Angevin, Bernard Escudier, Jürgen E. Gschwend, Michael Shi and Daniel Castellano and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Chia‐Chi Lin

43 papers receiving 826 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chia‐Chi Lin Taiwan 15 356 340 297 108 106 44 835
Alberto D’Angelo United Kingdom 18 449 1.3× 382 1.1× 348 1.2× 102 0.9× 188 1.8× 59 1000
Júlio Oliveira Portugal 18 502 1.4× 412 1.2× 283 1.0× 234 2.2× 208 2.0× 41 1.1k
William Berry United States 8 226 0.6× 252 0.7× 297 1.0× 73 0.7× 164 1.5× 16 675
Hong-Yun Zhao China 13 394 1.1× 220 0.6× 321 1.1× 68 0.6× 82 0.8× 21 775
Xiang Hu China 21 474 1.3× 302 0.9× 230 0.8× 173 1.6× 200 1.9× 62 979
Qiuning Zhang China 14 179 0.5× 247 0.7× 190 0.6× 71 0.7× 111 1.0× 70 590
Bingyi Lin China 18 190 0.5× 169 0.5× 455 1.5× 101 0.9× 183 1.7× 48 910
Yixing Chen China 16 243 0.7× 219 0.6× 257 0.9× 223 2.1× 111 1.0× 49 782

Countries citing papers authored by Chia‐Chi Lin

Since Specialization
Citations

This map shows the geographic impact of Chia‐Chi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia‐Chi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia‐Chi Lin more than expected).

Fields of papers citing papers by Chia‐Chi Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chia‐Chi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia‐Chi Lin. The network helps show where Chia‐Chi Lin may publish in the future.

Co-authorship network of co-authors of Chia‐Chi Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Chia‐Chi Lin. A scholar is included among the top collaborators of Chia‐Chi Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia‐Chi Lin. Chia‐Chi Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ou, Sai‐Hong Ignatius, Benjamin Solomon, Benjamin Besse, et al.. (2024). Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. Journal of Thoracic Oncology. 20(4). 513–520. 6 indexed citations
2.
Yang, Yung‐Ning, et al.. (2023). Acrylamide, an air pollutant, enhances allergen-induced eosinophilic lung inflammation via group 2 innate lymphoid cells. Mucosal Immunology. 17(1). 13–24. 11 indexed citations
3.
Lin, Chia‐Chi, Jaspreet Singh Grewal, David Sommerhalder, et al.. (2022). A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). e15052–e15052. 9 indexed citations
4.
Shum, Elaine, Yasir Y. Elamin, Zofia Piotrowska, et al.. (2022). A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.. Journal of Clinical Oncology. 40(16_suppl). TPS9156–TPS9156. 15 indexed citations
5.
Liang, Cher‐Wei, et al.. (2021). Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology. 148(7). 1803–1811. 4 indexed citations
6.
Liao, Wei‐Yu, Chao‐Chi Ho, Kuan‐Yu Chen, et al.. (2019). Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients. European Journal of Cancer. 117. 107–115. 30 indexed citations
7.
Wu, Tinghui, Emily Han-Chung Hsiue, Jih‐Hsiang Lee, et al.. (2018). Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients. Clinical Lung Cancer. 19(3). e361–e372. 19 indexed citations
8.
9.
Tahara, Makoto, Kei Muro, Yasuhisa Hasegawa, et al.. (2017). Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012. Cancer Science. 109(3). 771–776. 40 indexed citations
10.
Liao, Bin-Chi, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2015). Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology. 27(2). 94–101. 118 indexed citations
11.
Shao, Yu‐Yun, et al.. (2015). 401P Fentanyl patch is the most common strong opioids in Taiwan cancer patients. Annals of Oncology. 26. ix111–ix111. 1 indexed citations
12.
Escudier, Bernard, Viktor Grünwald, Alain Ravaud, et al.. (2014). Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research. 20(11). 3012–3022. 49 indexed citations
13.
Bang, Yung‐Jue, Wu‐Chou Su, Do‐Hyun Nam, et al.. (2014). Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2520–2520. 41 indexed citations
14.
Angevin, Eric, José A. López-Martín, Chia‐Chi Lin, et al.. (2013). Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 19(5). 1257–1268. 103 indexed citations
15.
Chen, Te-Hao, Chia‐Chi Lin, & Pei‐Jie Meng. (2013). Zinc oxide nanoparticles alter hatching and larval locomotor activity in zebrafish (Danio rerio). Journal of Hazardous Materials. 277. 134–140. 105 indexed citations
16.
17.
Shao, Yu‐Yun, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2010). Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.. PubMed. 9(49). 538–45. 12 indexed citations
18.
Lin, Chia‐Chi & James Chih‐Hsin Yang. (2009). Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Targeted Oncology. 4(1). 37–44. 10 indexed citations
19.
20.
Lin, Chia‐Chi, Kun‐Huei Yeh, James Chih‐Hsin Yang, et al.. (2007). Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anti-Cancer Drugs. 18(6). 703–708. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberto D’Angelo Breakdown of academic impact, for papers by Júlio Oliveira Breakdown of academic impact, for papers by William Berry Breakdown of academic impact, for papers by Hong-Yun Zhao Breakdown of academic impact, for papers by Xiang Hu Breakdown of academic impact, for papers by Qiuning Zhang Breakdown of academic impact, for papers by Bingyi Lin Breakdown of academic impact, for papers by Yixing Chen
Rankless by CCL
2026